Oramed Pharmaceuticals Inc. (ORMP) stock declines during after-hour, despite any current update.


Oramed Pharmaceuticals Inc. (NASDAQ: ORMP) stock plunged by 6.49% at last close while the ORMP stock price fell by 1.15% in the after-hours trading. Oramed Pharmaceuticals is a leader in the area of orally administered solutions for pharmaceuticals that are now administered through injection. Oramed, which was founded in 2006 and has offices in the US and Israel, has developed a revolutionary Protein Oral Delivery (POD) technology.

>> 7 Top Picks for the Post-Pandemic Economy << 

ORMP stock’ Recent Development

Oramed Pharmaceuticals has registered more than half of the individuals in its Phase 2 trial of ORMD-0801, an oral insulin capsule for the treatment of non-alcoholic steatohepatitis (NASH). Patients are still being screened in the United States and Israel.

Top 5 EV Tech Stocks to Buy for 2023

The electric vehicle boom is accelerating – and fast. According a new report published by BloombergNEF, annual spending on passenger EVs hit $388 billion in 2022, up 53% from the year before. Like we said, the boom is accelerating – and the time to buy EV-related tech stocks is now. Get our free report, "Top 5 EV Tech Stocks to Buy for 2023".

Click Here to Download the FREE Report.


Read More

ORMD-0801’s safety and potential efficacy in Type 2 diabetic patients with NASH is being studied in a double-blind, multi-center experiment. Following 12 weeks of dosage, MRI-PDFF will be used to assess efficacy outcomes such as percentage change in liver fat content, hepatic fibrosis, and liver steatosis compared to baseline. By 2029, the world market for NASH medications is estimated to reach $84 billion.

Non-alcoholic steatohepatitis (NASH) is a dangerous, serious liver disease characterised by a build-up of fat in the liver, inflammation, liver cell destruction, and, in rare cases, liver scarring. NASH can lead to cirrhosis, liver cancer, liver failure, and even fatality over time. There is presently no globally authorised medication for the treatment of NASH, leaving patients with the disease with few treatment alternatives.

Oramed Chief Executive Officer, Nadav Kidron stated,

ORMD-0801 has the ability to enhance results for people with both NASH and diabetes, as more than half of NASH patients have diabetes. NASH is a disease with a substantial unmet medical need because no medications have been licenced to treat it, despite the fact that it is the primary cause of liver transplants in the United States. They’re thrilled to build on the findings of their pilot research, which demonstrated a decrease in liver fat content, to indicate that ORMD-0801 has the potential to benefit patients with NASH.


Please enter your comment!
Please enter your name here